These numbers decreased over time in the second year to respectively, 3.17☓.22 for FU for 5.59±4.37 for IVI visits. Number of FU and IVI visitsĭuring the first year, the mean visits numbers were 9.9 ± 4.8 for FU for 6.7 ± 5.6 for IVI. Nevertheless, the period between the 12th and 18th month seemed to be a turning point in the evolution of this disease. This gap in VA gain during the first 18 months was the largest detected but was not significant. In this analysis, the VA gain was ranging from 17% to 20% for the first 18 months, but only from 9 to 10% after 18 months. At 24 months, the VA curve went up slightly again, this difference was not statistically significant (Figure 1).įigure 2 shows the proportion of patients with loss, stability, or a gain of 15 letters or more. There was no statistical difference between 12 and 18 months. At 12 and 18 months, the VA slightly decreased. VA (measured by ETDRS and Snellen equivalent) positively evolved up to 6 months with a gradual and significant increase both for ETDRS and Snellen measurements: respectively from 51.1☒2.4 to 55.5☒0.7 letters (p=0.0069), and from 0.31☐.22 to 0.39☐.26 (p=0.0009). Visual acuity (ETDRS scores) during the 24-month follow-up period (144 patients 165 eyes). Evolution of ETDRS score and SNELLEN scale from the initial visit and during the 24-month follow up period (144 patients 165 eyes).įigure 2. Quantitative variables are expressed as mean + Standard Deviation (SD) or as median with Confidence Interval 95%. Patients’ characteristics in the 2-year analysis (n=144). All the patients’ characteristics are detailed in table 1. Major medical histories were related to weak cardiovascular conditions, usually observed in elderly patients: i.e., arterial hypertension (54%), dyslipidemia (33%), and diabetes (17%). The population was characterized by a typical prevalence of women (67.36%) and older age (mean age 78.6 ± 8.2 years). Results 2-year resultsĭuring the study period, 144 consecutive patients (165 eyes) were included. ![]() The results of the multivariate analysis are presented as odds ratios (OR) with 95%CI.Īll statistical analyses were performed using SAS software version 9.1 (SAS Institute Inc., Cary, NC). In univariate analysis crude, comparisons regarding categorical variables were carried out using the χ²-test or the Fisher test. ![]() Independent factors for VA evolution were assessed using univariate analysis which was followed up with a multivariate analysis. The ETDRS scores at 4, 6, 8 and 12 months were significantly higher with AMD-dedicated vs standard consultations (p0.05 was considered statistically significant. ![]() ![]() The initial NV type did not affect AV evolution. Patients with induction phase had 3.5-times less chance of VA increase (p=0.0050). Induction phase did not significantly affect VA evolution (except at 6 months). R esults: Two-year analysis (n=144 patients): VA increased significantly between baseline and 6 months (p=0.0009 and p=0.0069). VA evolution and monitoring quality (FU number, IVI visit number) were analyzed up to 5 years. The secondary objectives were to assess the role of the following parameters on VA evolution: Follow-up (FU) and IVI visit numbers, treatment adherence (or delay between FU and IVI), neo-vessel (NV) types, induction phase or not, AMD–dedicated or standard consultation and to identify predictive factors for VA change. The primary objective was to study VA evolution, assessed by ETDRS and Snellen equivalent, over time. Methods: All consecutive patients treated in the ophthalmologic department from August 2011 to August 2013 were retrospectively enrolled.Īll patients had PRN monthly monitoring, either during AMD–dedicated or standard consultations. Purpose: In this study we aimed to describe visual acuity (VA) evolution and assess the benefit of personalized monitoring in a population of patients treated in real life for wet age-related macular degeneration (AMD) with ranibizumab intravitreal injections (IVI) using pro re nata (PRN) regimen for 5 years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |